For Public Release
NZX Limited
Wellington

27 November 2023

Cannasouth Investor Call

Cannasouth Limited (**NZX:CBD**) will host an online investor call on Wednesday, 29 November 2023, to discuss the Company's strategy to drive sales of its recently verified products and meet its revenue and operating cashflow targets.

The call is scheduled to begin at 11:00am NZDT, (9:00am AEDT).

Zoom Meeting Details

https://us06web.zoom.us/j/9946977651?omn=83610265728

Meeting ID: 994 697 7651

Cannasouth currently has two investment offers open.

1. Cannasouth opened a 1 for 8 pro-rata renounceable rights issue on 22 November 2023. The Rights Offer closes at 5:00pm on Thursday, 7 December 2023.

2. Cannasouth launched a wholesale offer of secured convertible notes on 2 November 2023.

Further information on these offers can be found at https://www.cannasouth.co.nz/investors/ or https://www.nzx.com/companies/CBD/announcements .

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas
CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster
CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited
Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: https://www.cannasouth.co.nz/about/media/